http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#Head http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#assertion http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#provenance http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#pubinfo http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00051 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association http://www.w3.org/2000/01/rdf-schema#label imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 1 1 juvenile idiopathic arthritis jia 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 adult crohn s disease cd 1 5 ulcerative colitis uc 1 6 plaque psoriasis ps 1 7 imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other non biologic disease modifying anti rheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 3 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with non biologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6 mercaptopurine 6 mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 14 7 imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warning 5 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00051 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#provenance http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#pubinfo http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#sig http://purl.org/nanopub/x/hasSignature FK3UdugEzUUEdt3gs/FacJh6iG7lX4pQvXLtuwpv0MMuWraq7m3naNOsDC2nTcjugebByYlMOe7By2tvjAzv7Xay/1dG8wztuWq7u4IDiuga6RyFvTR9t/i2WsP+8Y4tXO2Sk9kBtDTG7EBB4bY/BiJ7rePS8jDM/eJCVEv40WY= http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://purl.org/dc/terms/created 2021-06-12T13:37:05.075+02:00 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAK0oTPbFfZ7PrrVZ_1fk1iPFa_VNdR40UNSeRVpK67eg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs